VERAXA Biotech (NASDAQ: VRXA) has appointed Raju Willener as chief financial officer, effective immediately, a move that brings more than three decades of international capital-markets experience to the biotechnology company as it works to advance its oncology pipeline. Willener will report to Chief Executive Officer and co-founder Christoph Antz, Ph.D. (https://ibn.fm/Eibml).
Willener’s career spans investment banking, corporate finance, asset management and strategic leadership across the United States, Europe and Asia. Before joining VERAXA, he served as director of corporate development at Exentis Group AG. His extensive background in capital markets is expected to be instrumental as VERAXA seeks to fund and develop its proprietary BiTAC platform, which is centered on antibody-drug conjugates (ADCs) and T-cell engagers.
The appointment comes at a critical juncture for VERAXA, which has reported encouraging early data for its BiTAC technologies, including an in-vitro proof of concept for its BiTAC-ADC platform. These technologies are designed to address unmet needs in cancer treatment by combining the targeting capabilities of antibodies with the potent cell-killing effects of drugs or immune cells. The BiTAC-ADC platform, in particular, aims to deliver cytotoxic payloads more precisely to tumor cells, potentially reducing off-target toxicity and improving therapeutic indices.
Bringing on a CFO with Willener’s depth of experience signals VERAXA’s intent to strengthen its financial strategy and investor relations as it transitions from preclinical research toward clinical development. In the competitive oncology space, where companies often require substantial capital to fund lengthy and expensive trials, having a leader with expertise in investment banking and asset management could be crucial for securing financing, managing partnerships, and navigating public markets. Willener’s international perspective may also aid VERAXA in expanding its global footprint and accessing diverse sources of capital.
VERAXA’s pipeline includes both antibody-drug conjugates and T-cell engagers, two modalities that have garnered significant attention in recent years for their potential to treat a range of cancers. The company’s BiTAC platform appears to be a differentiated approach that could offer advantages over existing therapies. The reported in-vitro proof of concept for BiTAC-ADC is an early but important milestone, suggesting that the technology is viable and worthy of further investment. As VERAXA moves forward, the combination of a seasoned financial executive and promising scientific data could position the company to accelerate development and create value for shareholders.
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA. For full terms of use and disclaimers applicable to all content provided by IBN, visit https://IBN.ai/Disclaimer.
